Seizures in low-grade gliomas: natural history, pathogenesis, and outcome after treatments
Seizures represent a common symptom in low-grade gliomas; when uncontrolled, they significantly contribute to patient morbidity and negatively impact quality of life. Tumor location and histology influence the risk for epilepsy. The pathogenesis of tumor-related epilepsy is multifactorial and may di...
Gespeichert in:
| Veröffentlicht in: | Neuro-oncology (Charlottesville, Va.) Va.), 2012-09, Vol.14 Suppl 4 (suppl 4), p.iv55-iv64 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | iv64 |
|---|---|
| container_issue | suppl 4 |
| container_start_page | iv55 |
| container_title | Neuro-oncology (Charlottesville, Va.) |
| container_volume | 14 Suppl 4 |
| creator | Rudà, Roberta Bello, Lorenzo Duffau, Hugues Soffietti, Riccardo |
| description | Seizures represent a common symptom in low-grade gliomas; when uncontrolled, they significantly contribute to patient morbidity and negatively impact quality of life. Tumor location and histology influence the risk for epilepsy. The pathogenesis of tumor-related epilepsy is multifactorial and may differ among tumor histologies (glioneuronal tumors vs diffuse grade II gliomas). Gross total resection is the strongest predictor of seizure freedom in addition to clinical factors, such as preoperative seizure duration, type, and control with antiepileptic drugs (AEDs). Epilepsy surgery may improve seizure control. Radiotherapy and chemotherapy with alkylating agents (procarbazine + CCNU+ vincristine, temozolomide) are effective in reducing the frequency of seizures in patients with pharmacoresistant epilepsy. Newer AEDs (levetiracetam, topiramate, lacosamide) seem to be better tolerated than the old AEDs (phenobarbital, phenytoin, carbamazepine), but there is lack of evidence regarding their superiority in terms of efficacy. |
| doi_str_mv | 10.1093/neuonc/nos199 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3480244</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1551613609</sourcerecordid><originalsourceid>FETCH-LOGICAL-c420t-52e48338324c5f499dc221829cdf76bbd426767bcfca6399a2e529e243c0a04b3</originalsourceid><addsrcrecordid>eNqFkTtvFTEQha0IlIRAmRa5pMgSe_zYdQokFPGSIlFAGhrL652912jXvrG9oPDr2XCTCCqqGWk-nTkzh5BTzl5zZsR5xCVFfx5T4cYckGOuQDSq0_rJnx6aTvH2iDwr5TtjwJXmh-QIBDOqE_yYfPuC4deSsdAQ6ZR-NpvsBqSbKaTZlQsaXV2ym-g2lJry7RndubpNG4xYQjmjLg40LdWnGakbK2ZaM7o6Y6zlOXk6uqngi_t6Qq7fv_t6-bG5-vzh0-Xbq8ZLYLVRgLITohMgvRqlMYMH4B0YP4yt7vtBgm512_vROy2McYAKDIIUnjkme3FC3ux1d0s_4-DX3atju8thdvnWJhfsv5MYtnaTflghOwZSrgKv7gVyulmwVDuH4nGaXMS0FMuV4poLvb77vygHBbKVol3RZo_6nErJOD464szeRWf30dl9dCv_8u8zHumHrMRvrNCYqg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1125247437</pqid></control><display><type>article</type><title>Seizures in low-grade gliomas: natural history, pathogenesis, and outcome after treatments</title><source>Oxford University Press Journals All Titles (1996-Current)</source><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Rudà, Roberta ; Bello, Lorenzo ; Duffau, Hugues ; Soffietti, Riccardo</creator><creatorcontrib>Rudà, Roberta ; Bello, Lorenzo ; Duffau, Hugues ; Soffietti, Riccardo</creatorcontrib><description>Seizures represent a common symptom in low-grade gliomas; when uncontrolled, they significantly contribute to patient morbidity and negatively impact quality of life. Tumor location and histology influence the risk for epilepsy. The pathogenesis of tumor-related epilepsy is multifactorial and may differ among tumor histologies (glioneuronal tumors vs diffuse grade II gliomas). Gross total resection is the strongest predictor of seizure freedom in addition to clinical factors, such as preoperative seizure duration, type, and control with antiepileptic drugs (AEDs). Epilepsy surgery may improve seizure control. Radiotherapy and chemotherapy with alkylating agents (procarbazine + CCNU+ vincristine, temozolomide) are effective in reducing the frequency of seizures in patients with pharmacoresistant epilepsy. Newer AEDs (levetiracetam, topiramate, lacosamide) seem to be better tolerated than the old AEDs (phenobarbital, phenytoin, carbamazepine), but there is lack of evidence regarding their superiority in terms of efficacy.</description><identifier>ISSN: 1522-8517</identifier><identifier>EISSN: 1523-5866</identifier><identifier>DOI: 10.1093/neuonc/nos199</identifier><identifier>PMID: 23095831</identifier><language>eng</language><publisher>England: Oxford University Press</publisher><subject>Anticonvulsants - therapeutic use ; Brain Neoplasms - complications ; Brain Neoplasms - pathology ; Glioma - complications ; Glioma - pathology ; Humans ; Neoplasm Grading ; Orginal ; Seizures - etiology ; Seizures - therapy ; Treatment Outcome</subject><ispartof>Neuro-oncology (Charlottesville, Va.), 2012-09, Vol.14 Suppl 4 (suppl 4), p.iv55-iv64</ispartof><rights>The Author(s) 2012. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. 2012</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c420t-52e48338324c5f499dc221829cdf76bbd426767bcfca6399a2e529e243c0a04b3</citedby><cites>FETCH-LOGICAL-c420t-52e48338324c5f499dc221829cdf76bbd426767bcfca6399a2e529e243c0a04b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3480244/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3480244/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23095831$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rudà, Roberta</creatorcontrib><creatorcontrib>Bello, Lorenzo</creatorcontrib><creatorcontrib>Duffau, Hugues</creatorcontrib><creatorcontrib>Soffietti, Riccardo</creatorcontrib><title>Seizures in low-grade gliomas: natural history, pathogenesis, and outcome after treatments</title><title>Neuro-oncology (Charlottesville, Va.)</title><addtitle>Neuro Oncol</addtitle><description>Seizures represent a common symptom in low-grade gliomas; when uncontrolled, they significantly contribute to patient morbidity and negatively impact quality of life. Tumor location and histology influence the risk for epilepsy. The pathogenesis of tumor-related epilepsy is multifactorial and may differ among tumor histologies (glioneuronal tumors vs diffuse grade II gliomas). Gross total resection is the strongest predictor of seizure freedom in addition to clinical factors, such as preoperative seizure duration, type, and control with antiepileptic drugs (AEDs). Epilepsy surgery may improve seizure control. Radiotherapy and chemotherapy with alkylating agents (procarbazine + CCNU+ vincristine, temozolomide) are effective in reducing the frequency of seizures in patients with pharmacoresistant epilepsy. Newer AEDs (levetiracetam, topiramate, lacosamide) seem to be better tolerated than the old AEDs (phenobarbital, phenytoin, carbamazepine), but there is lack of evidence regarding their superiority in terms of efficacy.</description><subject>Anticonvulsants - therapeutic use</subject><subject>Brain Neoplasms - complications</subject><subject>Brain Neoplasms - pathology</subject><subject>Glioma - complications</subject><subject>Glioma - pathology</subject><subject>Humans</subject><subject>Neoplasm Grading</subject><subject>Orginal</subject><subject>Seizures - etiology</subject><subject>Seizures - therapy</subject><subject>Treatment Outcome</subject><issn>1522-8517</issn><issn>1523-5866</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkTtvFTEQha0IlIRAmRa5pMgSe_zYdQokFPGSIlFAGhrL652912jXvrG9oPDr2XCTCCqqGWk-nTkzh5BTzl5zZsR5xCVFfx5T4cYckGOuQDSq0_rJnx6aTvH2iDwr5TtjwJXmh-QIBDOqE_yYfPuC4deSsdAQ6ZR-NpvsBqSbKaTZlQsaXV2ym-g2lJry7RndubpNG4xYQjmjLg40LdWnGakbK2ZaM7o6Y6zlOXk6uqngi_t6Qq7fv_t6-bG5-vzh0-Xbq8ZLYLVRgLITohMgvRqlMYMH4B0YP4yt7vtBgm512_vROy2McYAKDIIUnjkme3FC3ux1d0s_4-DX3atju8thdvnWJhfsv5MYtnaTflghOwZSrgKv7gVyulmwVDuH4nGaXMS0FMuV4poLvb77vygHBbKVol3RZo_6nErJOD464szeRWf30dl9dCv_8u8zHumHrMRvrNCYqg</recordid><startdate>201209</startdate><enddate>201209</enddate><creator>Rudà, Roberta</creator><creator>Bello, Lorenzo</creator><creator>Duffau, Hugues</creator><creator>Soffietti, Riccardo</creator><general>Oxford University Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7TK</scope><scope>5PM</scope></search><sort><creationdate>201209</creationdate><title>Seizures in low-grade gliomas: natural history, pathogenesis, and outcome after treatments</title><author>Rudà, Roberta ; Bello, Lorenzo ; Duffau, Hugues ; Soffietti, Riccardo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c420t-52e48338324c5f499dc221829cdf76bbd426767bcfca6399a2e529e243c0a04b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Anticonvulsants - therapeutic use</topic><topic>Brain Neoplasms - complications</topic><topic>Brain Neoplasms - pathology</topic><topic>Glioma - complications</topic><topic>Glioma - pathology</topic><topic>Humans</topic><topic>Neoplasm Grading</topic><topic>Orginal</topic><topic>Seizures - etiology</topic><topic>Seizures - therapy</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rudà, Roberta</creatorcontrib><creatorcontrib>Bello, Lorenzo</creatorcontrib><creatorcontrib>Duffau, Hugues</creatorcontrib><creatorcontrib>Soffietti, Riccardo</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Neurosciences Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Neuro-oncology (Charlottesville, Va.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rudà, Roberta</au><au>Bello, Lorenzo</au><au>Duffau, Hugues</au><au>Soffietti, Riccardo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Seizures in low-grade gliomas: natural history, pathogenesis, and outcome after treatments</atitle><jtitle>Neuro-oncology (Charlottesville, Va.)</jtitle><addtitle>Neuro Oncol</addtitle><date>2012-09</date><risdate>2012</risdate><volume>14 Suppl 4</volume><issue>suppl 4</issue><spage>iv55</spage><epage>iv64</epage><pages>iv55-iv64</pages><issn>1522-8517</issn><eissn>1523-5866</eissn><abstract>Seizures represent a common symptom in low-grade gliomas; when uncontrolled, they significantly contribute to patient morbidity and negatively impact quality of life. Tumor location and histology influence the risk for epilepsy. The pathogenesis of tumor-related epilepsy is multifactorial and may differ among tumor histologies (glioneuronal tumors vs diffuse grade II gliomas). Gross total resection is the strongest predictor of seizure freedom in addition to clinical factors, such as preoperative seizure duration, type, and control with antiepileptic drugs (AEDs). Epilepsy surgery may improve seizure control. Radiotherapy and chemotherapy with alkylating agents (procarbazine + CCNU+ vincristine, temozolomide) are effective in reducing the frequency of seizures in patients with pharmacoresistant epilepsy. Newer AEDs (levetiracetam, topiramate, lacosamide) seem to be better tolerated than the old AEDs (phenobarbital, phenytoin, carbamazepine), but there is lack of evidence regarding their superiority in terms of efficacy.</abstract><cop>England</cop><pub>Oxford University Press</pub><pmid>23095831</pmid><doi>10.1093/neuonc/nos199</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1522-8517 |
| ispartof | Neuro-oncology (Charlottesville, Va.), 2012-09, Vol.14 Suppl 4 (suppl 4), p.iv55-iv64 |
| issn | 1522-8517 1523-5866 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3480244 |
| source | Oxford University Press Journals All Titles (1996-Current); MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central |
| subjects | Anticonvulsants - therapeutic use Brain Neoplasms - complications Brain Neoplasms - pathology Glioma - complications Glioma - pathology Humans Neoplasm Grading Orginal Seizures - etiology Seizures - therapy Treatment Outcome |
| title | Seizures in low-grade gliomas: natural history, pathogenesis, and outcome after treatments |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T22%3A44%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Seizures%20in%20low-grade%20gliomas:%20natural%20history,%20pathogenesis,%20and%20outcome%20after%20treatments&rft.jtitle=Neuro-oncology%20(Charlottesville,%20Va.)&rft.au=Rud%C3%A0,%20Roberta&rft.date=2012-09&rft.volume=14%20Suppl%204&rft.issue=suppl%204&rft.spage=iv55&rft.epage=iv64&rft.pages=iv55-iv64&rft.issn=1522-8517&rft.eissn=1523-5866&rft_id=info:doi/10.1093/neuonc/nos199&rft_dat=%3Cproquest_pubme%3E1551613609%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1125247437&rft_id=info:pmid/23095831&rfr_iscdi=true |